ABLi Therapeutics
Pre-clinicalDeveloping disease-modifying therapies for Parkinson's and related neurodegenerative diseases through targeting Abelson Tyrosine Kinases.
Founded
2016
Focus
AntibodiesBiologicsSmall Molecules
About
Developing disease-modifying therapies for Parkinson's and related neurodegenerative diseases through targeting Abelson Tyrosine Kinases.
Funding History
2Total raised: $100M
Series B$60MF-Prime CapitalNov 15, 2023
Series A$40MOrbiMedMar 15, 2022
Company Info
TypePrivate
Founded2016
LocationCambridge, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile